Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Benjamin N Rome und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Hiccup, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Benjamin N Rome
Förderung
- Arnold Ventures
Zitieren
APA
Rome, B. N., & Kesselheim, A. S. (2023). Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups. Arthritis & Rheumatology. https://doi.org/10.1002/art.42520
Vancouver
Rome BN, Kesselheim AS. Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups. Arthritis & Rheumatology. 2023. doi:10.1002/art.42520
BibTeX
@article{Rome2023,
author = {Rome, Benjamin N and Kesselheim, Aaron S},
title = {Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42520}
}
EUVIMED